Lyfebulb Partners With Novo Nordisk A/S to Support Patient-Driven Innovations for People With Diabetes
(firmenpresse) - NEW YORK, NY -- (Marketwired) -- 07/19/16 -- Lyfebulb, a patient-centric company that empowers patient entrepreneurs to deliver innovative products and solutions to patients living with chronic disease, announces a partnership with Novo Nordisk A/S, a global healthcare company driving change to defeat diabetes.
The partnership will focus on patient entrepreneurs developing innovative ideas and concepts for better management of diabetes using consumer or medical devices, or healthcare information technology. Linking entrepreneurs with senior device researchers from Novo Nordisk will spotlight the entrepreneurs' efforts and ideas, and provide professional discussion, direction, and inspiration.
"This partnership with Novo Nordisk marks a milestone for Lyfebulb as a young organization with a strong commitment to patient-driven innovation and laser-focus on improving the quality of life for those living with chronic diseases such as diabetes," said Dr. Karin Hehenberger, CEO and Founder of Lyfebulb. "We are excited to expand our Lyfebulb Entrepreneur Circle, which provides exposure to an exclusive group of patient entrepreneurs who seek to truly transform their business. These entrepreneurs may help to transform the lives of patients."
Senior Vice President for Novo Nordisk Device R&D Kenneth Strømdahl stated: "Having the patient at the center of everything we do directs us in our daily work. My team and I look forward to the unique opportunity to learn from and be inspired by the patient entrepreneurs."
Lyfebulb is a business focused on bringing innovative products and solutions focused on chronic disease to market. Lyfebulb serves as a bridge between patients and industry, and its mission is to improve the quality of life of those living with chronic disease NOW.
See , , , , , and .
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 75 countries and markets its products in more than 180 countries. For more information, visit , , , ,
Karin Hehenberger, MD, PhD
CEO Lyfebulb
phone: 917-575-0210
email:
Sean Leous
Managing Director
PCG Advisory Group
phone: 646-863-8998
email:
People's RevolutionKelly Cutrone & Simone Francese
62 Grand Street, 3rd Floor
New York, New York 10013
212.274.0400
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 19.07.2016 - 12:30 Uhr
Sprache: Deutsch
News-ID 483997
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Alternative
Diese Pressemitteilung wurde bisher 292 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Lyfebulb Partners With Novo Nordisk A/S to Support Patient-Driven Innovations for People With Diabetes"
steht unter der journalistisch-redaktionellen Verantwortung von
Lyfebulb (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
